Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, will share pre-clinical data that shows the anti-cancer activity of its lead asset YB-200 at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA, on November 11, 2022.Dr. Katrin Rupalla, CEO, Ymmunobio AG, and Dr. Bernhard B. Singer, University Essen/Duisburg, Germany, will answer questions on findings demonstrating how Ymmunobio’s monoclonal antibody YB-200 significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment.
The full text of this year’s SITC abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement at 8:00 a.m. EST on Tuesday, Nov. 7, 2022 and available from the SITC website.
Co-authors of Ymmunobio’s poster presentation are Michel Janicot, PhD, Ymmunobio, Alexej Schmidt, PhD, University of Umea, Sweden, and Iris Helfrich, PhD, Professor at the University of Munich, Germany.